AcquisitionOther
Carlyle and SK Capital Partners acquired bluebird bio, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Carlyle and SK Capital Partners -> bluebird bio, Inc. · $3.00 per share + $6.84 CVR or $5.00 per share
only viable option for stockholders to receive consideration for their shares
Open source record (SEC) ↗